DESMOPRESSIN ACETATE | N019955 | FERRING PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Ferring Pharmaceuticals Inc. et al v. Serenity Pharmaceuticals, LLC et al 9 patentsdesmopressin | S.D.N.Y. | 2017-12-20 | Terminated 2020-08-21 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Hyman, Phelps & McNamara, P.C. FDA-2026-P-3844 Hyman, Phelps & McNamara, P.C. filed this suitability petition under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting that the FDA declare Desmopressin Acetate Tablets in 0.05 mg and 0.15 mg strengths suitable for submission as an Abbreviated New Drug Application, with the | Suitability | 2026-04-09 | Open | Hyman |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.